Epizyme Inc (NASDAQ:EPZM) has been assigned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $17.14.
A number of equities analysts recently issued reports on EPZM shares. ValuEngine downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. BidaskClub downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a report on Tuesday, September 24th. Zacks Investment Research downgraded shares of Epizyme from a “buy” rating to a “hold” rating and set a $15.00 price objective on the stock. in a report on Wednesday, August 14th. Wedbush reissued an “outperform” rating and issued a $21.00 price objective on shares of Epizyme in a report on Wednesday, June 12th. Finally, HC Wainwright set a $25.00 price objective on shares of Epizyme and gave the stock a “buy” rating in a report on Monday, June 24th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aperio Group LLC bought a new stake in Epizyme during the 2nd quarter worth approximately $72,000. Rockefeller Capital Management L.P. bought a new stake in Epizyme during the 2nd quarter worth approximately $88,000. United Services Automobile Association bought a new stake in Epizyme during the 2nd quarter worth approximately $134,000. BP PLC bought a new stake in Epizyme during the 2nd quarter worth approximately $177,000. Finally, HarbourVest Partners LLC bought a new stake in Epizyme during the 2nd quarter worth approximately $177,000. Institutional investors own 86.30% of the company’s stock.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). The company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $0.32 million. The company’s revenue was down 50.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.42) earnings per share. Analysts expect that Epizyme will post -2.2 earnings per share for the current year.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.